Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia
Rodrigues Amorim, Daniela; Rivera Baltanás, Tania; Vallejo Curto, María del Carmen; Rodriguez Jamardo, Cynthia; de las Heras, Elena; Barreiro Villar, Carolina; Blanco Formoso, María; Fernández Palleiro, Patricia; Álvarez Ariza, María; López, Marta; García Caballero, Alejandro; Olivares, José Manuel; Spuch Calvar, Carlos
FECHA:
2020-08-31
IDENTIFICADOR UNIVERSAL: http://hdl.handle.net/11093/3923
VERSIÓN EDITADA: https://www.nature.com/articles/s41598-020-71060-4
TIPO DE DOCUMENTO: article
RESUMEN
Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of β-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of β-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, β-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ